Skip to content

JBIO JBIO Quick ratio

Quick ratio at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
2.9×+1.0×
Vera Therapeutics logo
Vera TherapeuticsVERA
13.6×-14.0×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
7.6×-0.7×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
7.7×-14.9×
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
10.3×-1.3×

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.33B+318%
Enterprise value$1.28B

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Calculated from JBIO’s reported figures.

Based on the most recent quarter.

The official record: JBIO’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about JBIO's quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JBIO's quick ratio?
JBIO (JBIO) reported quick ratio of 14.3× in Q1 2026.
How has JBIO's quick ratio changed year-over-year?
JBIO's quick ratio decreased by 55.4% year-over-year, from 32× to 14.3×.
What is the long-term trend for JBIO's quick ratio?
Over 5 years (2020 to 2025), JBIO's quick ratio has grown at a 51.6% compound annual growth rate (CAGR), from 2.6× to 21.1×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.